Yes. GHK-Cu Troche is a compounded prescription preparation requiring a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required before dispensing to confirm clinical suitability and establish the appropriate dosing protocol.

GHK-Cu has a well-established safety profile based on its natural occurrence in human physiology. Troche-specific side effects are generally mild and may include: transient blue discoloration of saliva or oral mucosa during dissolution (normal and harmless — the copper complex color), mild oral sensitivity or transient irritation at the dissolution site during initial use, and occasional mild nausea or infrequent headache. Serious adverse effects have not been documented at therapeutic doses. Discontinue and contact your provider if you experience persistent oral irritation, swelling of the mouth or throat, or signs of a systemic allergic reaction.

Patients with Wilson's disease or copper metabolism disorders must not use this preparation without specialist supervision and close monitoring of copper status. Patients with active malignancy require oncology consultation and individualized risk-benefit assessment before initiating therapy. Safety during pregnancy and breastfeeding has not been established — use is not recommended. Pediatric use has not been studied. Patients with a history of any malignancy should discuss use with their provider.

Copper-chelating agents (D-penicillamine, trientine) will directly antagonize the copper component of GHK-Cu — concurrent use is contraindicated without specialist guidance. High-dose antioxidant supplementation may theoretically interact with copper-mediated redox activity. Patients on systemic immunosuppressive therapy require individualized evaluation due to GHK-Cu's immune gene-modulating activity. Provide a complete medication list before beginning treatment.

Patients with Wilson's disease or any copper metabolism disorder require specialist assessment before using any systemic copper-containing preparation. Those with a history of any malignancy should have their provider and oncologist review the appropriateness of GHK-Cu therapy. Patients with significant cardiovascular, hepatic, or renal disease require individualized evaluation. Your provider will determine appropriateness based on your complete medical history.